



DEPARTMENT OF MATERIALS SCIENCE AND ENGINEERING

Spring 2022 SEMINAR SERIES

PAUL MCCORMAC - CTO LEXEO THERAPEUTICS **DELIVERING THE PROMISE OF GENE THERAPY BEYOND RARE DISEASE**

You're going to need a bigger boat!!!

Recent approvals including Luxturna® and Zolgensma® have demonstrated the transformational impact AAV gene therapy can have for rare monogenic diseases. The approval and distribution of mRNA vaccines has demonstrated the potential for nucleic acid medicines to be impactful globally. This talk will focus on the historical context of AAV gene therapy development and manufacturing and to deliver these transformational medicines to very large patient populations by the application of bioprocess engineering and advanced analytics.

Paul McCormac, PhD, is the Chief Technical Officer of LEXEO Therapeutics. LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.

**WEDNESDAY
MARCH 16TH @ 2:30
MARYLAND HALL 110**



JOHNS HOPKINS
WHITING SCHOOL
of ENGINEERING

Materials Science and Engineering

@jhumaterials